The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease

Journal of the American College of Cardiology

Volumn 56, Issue 12, 2010, Pages 934-942

  Stone, Peter H ^a   Chaitman, Bernard R ^b   Stocke, Karen ^b   Sano, Junko ^b   Devault, Arthur ^c   Koch, Gary G ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c CV THERAPEUTICS INC   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

angina; exercise; ischemia; ranolazine

Indexed keywords

PLACEBO; RANOLAZINE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; EXERCISE; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXYGEN SUPPLY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATE PRESSURE PRODUCT; ST SEGMENT DEPRESSION; TREADMILL EXERCISE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 77956535593     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.042     Document Type: Article

References (26)

1. J. Abrams Clinical practice Chronic stable angina N Engl J Med 352 2005 2524 2533
2. B.R. Chaitman, S.L. Skettino, and J.O. Parker Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J Am Coll Cardiol 43 2004 1375 1382
3. M.F. Rousseau, H. Pouleur, G. Cocco, and A.A. Wolff Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris Am J Cardiol 95 2005 311 316
4. C.J. Pepine, and A.A. Wolff A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents Ranolazine Study Group Am J Cardiol 84 1999 46 50
5. B.R. Chaitman, C.J. Pepine, and J.O. Parker Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 291 2004 309 316
6. L. Belardinelli, J.C. Shyrock, and H. Fraser The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction Eur Heart J Suppl 8 Suppl 2006 A10 A13
7. D.G. Caralis, L. Shaw, and B. Bilgere Application of computerized exercise ECG digitization Interpretation in large clinical trials J Electrocardiol 25 1992 101 110
8. C.H.L.P. Malllinckrodt, D. Schnell, Y. Peng, and J.P. Mancuso Recommendations for the primary analysis of continuous end points in longitudinal clinical trials Drug Info J 42 2008 303 319
9. P.H. Stone, N.A. Gratsiansky, A. Blokhin, I.Z. Huang, and L. Meng Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial J Am Coll Cardiol 48 2006 566 575
10. D.A. Morrow, B.M. Scirica, and E. Karwatowska-Prokopczuk Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
11. W.E. Boden, R.A. O'Rourke, and K.K. Teo Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
12. D.G. Katritsis, and J.P. Ioannidis Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis Circulation 111 2005 2906 2912
13. R. Holubkov, W.K. Laskey, and A. Haviland Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry Am Heart J 144 2002 826 833 (Pubitemid 35335174)
14. R.J. Gibbons, J. Abrams, and K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable anginasummary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168 (Pubitemid 36044419)
15. S. Epstein, D.R. Redwood, and R.E. Goldstein Angina pectoris: pathophysiology, evaluation, and treatment Ann Intern Med 75 1971 263 296
16. P. Wang, H. Fraser, S.G. Lloyd, J.J. McVeigh, L. Belardinelli, and J.C. Chatham A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion J Pharmacol Exp Ther 321 2007 213 220
17. C. Antzelevitch, L. Belardinelli, and A.C. Zygmunt Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 2004 904 910 (Pubitemid 39136212)
18. Y. Song, J.C. Shryock, L. Wu, and L. Belardinelli Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes J Cardiovasc Pharmacol 44 2004 192 199
19. B.R. Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 2006 2462 2472
20. M.P. Chandler, W.C. Stanley, and H. Morita Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure Circ Res 91 2002 278 280
21. H. Fraser, L. Belardinelli, L. Wang, P.E. Light, J.J. McVeigh, and A.S. Clanachan Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts J Mol Cell Cardiol 41 2006 1031 1038
22. F.J. Klocke Ranolazine and the myocardial demand-supply balance J Am Coll Cardiol Img 2 2009 1310 1312
23. S.H. Deshmukh, S.R. Patel, and E. Pinassi Ranolazine improves endothelial function in patients with stable coronary artery disease Coron Artery Dis 20 2009 343 347
24. R. Venkataraman, L. Belardinelli, B. Blackburn, J. Heo, and A.E. Iskandrian A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images J Am Coll Cardiol Img 2 2009 1301 1309
25. S.L. Hale, J.A. Leeka, and R.A. Kloner Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel J Pharmacol Exp Ther 318 2006 418 423
26. A. MacInnes, D.A. Fairman, and P. Binding The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase Circ Res 93 2003 e26 e32